Literature DB >> 33414829

Hereditary Hemorrhagic Telangiectasia in a Sudanese Patient.

Omer Ali Mohamed Ahmed Elawad1, Ahmed Abdalazim Dafallah Albashir1,2, Mohammed Mahgoub Mirghani Ahmed1, Ahmed Ali Mohamed Ahmed Elawad1,2, Osman Eltieb Elbasheer Mohamed1.   

Abstract

BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) also known as Osler-Weber-Rendu syndrome is a rare autosomal dominant disorder, which results in vascular dysplasia affecting mainly visceral and mucocutaneous organs. Case Presentation. A 65-year-old woman with a 12-year history of recurrent spontaneous epistaxis presented with shortness of breath, easy fatigability, and bilateral lower limb edema. Her family history was significant for definite hereditary hemorrhagic telangiectasia in first-degree relatives. During the previous 15 days, she has experienced three episodes of recurrent nasal bleeding. She has a background of chronic mitral regurgitation. Physical examination revealed telangiectases in her tongue, lower lip, and hand in addition to signs of congestive heart failure. The patient met 3\4 Curacao criteria and had a definite HHT. Her laboratory workup revealed a hemoglobin count of 5.4 g/dl. Echocardiography revealed a left systolic ejection fraction of 51% with left atrial dilatation and severe mitral regurgitation. Chest X-ray showed features of cardiomegaly and pulmonary edema. The abdominal ultrasonography showed enlarged liver size with homogenous texture and congested hepatic veins without features of hepatic AVMs. She was treated with intravenous frusemide, iron supplement, tranexamic acid, blood transfusion, and nasal packing.
CONCLUSIONS: HTT usually passes unnoticed in Sudan. The rarity of HHT, difficulties in affording diagnostic imaging studies, and low clinical suspicion among doctors are important contributing factors. Anemia resulting from recurrent epistaxis might have an influential role in precipitating acute heart failure in those with chronic rheumatic valvular disease.
Copyright © 2020 Omer Ali Mohamed Ahmed Elawad et al.

Entities:  

Year:  2020        PMID: 33414829      PMCID: PMC7752298          DOI: 10.1155/2020/6395629

Source DB:  PubMed          Journal:  Case Rep Med


  8 in total

1.  Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial.

Authors:  E Yaniv; M Preis; J Shevro; B Nageris; T Hadar
Journal:  Rhinology       Date:  2011-06       Impact factor: 3.681

2.  Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia.

Authors:  Freya Droege; Kruthika Thangavelu; Boris A Stuck; Andreas Stang; Stephan Lang; Urban Geisthoff
Journal:  Vasc Med       Date:  2018-05-20       Impact factor: 3.239

Review 3.  Liver involvement in hereditary hemorrhagic telangiectasia (HHT).

Authors:  Guadalupe Garcia-Tsao
Journal:  J Hepatol       Date:  2007-01-02       Impact factor: 25.083

4.  The natural history of epistaxis in hereditary hemorrhagic telangiectasia.

Authors:  O S AAssar; C M Friedman; R I White
Journal:  Laryngoscope       Date:  1991-09       Impact factor: 3.325

Review 5.  Rendu-Osler-Weber disease: update of medical and dental considerations.

Authors:  E C te Veldhuis; A H te Veldhuis; F S van Dijk; M L Kwee; J M van Hagen; J A Baart; I van der Waal
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2008-02

6.  Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.

Authors:  Rosangela Invernizzi; Federica Quaglia; Catherine Klersy; Fabio Pagella; Federica Ornati; Francesco Chu; Elina Matti; Giuseppe Spinozzi; Sara Plumitallo; Pierangela Grignani; Carla Olivieri; Raffaella Bastia; Francesca Bellistri; Cesare Danesino; Marco Benazzo; Carlo L Balduini
Journal:  Lancet Haematol       Date:  2015-10-27       Impact factor: 18.959

7.  Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers.

Authors:  Hanny Al-Samkari; Hasan A Albitar; Scott E Olitsky; Marianne S Clancy; Vivek N Iyer
Journal:  Orphanet J Rare Dis       Date:  2019-11-14       Impact factor: 4.123

8.  The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia.

Authors:  Scott D Grosse; Sheree L Boulet; Althea M Grant; Mary M Hulihan; Marie E Faughnan
Journal:  Genet Med       Date:  2013-05-23       Impact factor: 8.822

  8 in total
  2 in total

1.  Hereditary hemorrhagic telangiectasia diagnosed by enteroscopy: a case report.

Authors:  Margarita Rey; Johana Milena Salazar; Drixie Dalyla Leal; Fernando Sierra; Erika Pérez; Jose De la Hoz; Gustavo Adolfo Reyes; Mariana Vásquez Roldán
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

2.  Right hemihepatectomy combined with ligation of the common hepatic artery and gastroduodenal artery for the treatment of intrahepatic HHT: A case report.

Authors:  Jifeng Xiang; Wei Xie; Cuncheng Zhang; Huaizhi Wang
Journal:  Front Surg       Date:  2022-08-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.